retatrutide ly3437943 phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Dyce | Retatrutide isn't just

At roughly 4-5x sales, L Catterton is pricing in a future where cottage cheese isnt just a resurgent category but a platform, a high-protein chassis that anchors entirely new product lines

Toyoda K

CagriSema's major obesity and type 2 diabetes programs are built around the cagrilintide/semaglutide combination

"By working with Eli Lilly to make the KwikPen accessible on Ro's platform, we're continuing to help patients access the latest treatments, in the most innovative form factors, at the lowest possible cost," said Zach Reitano, co-founder and CEO of Ro

Because they are FDA-approved for type II diabetes many physicians may not be aware of how helpful they can be, which means its up to you to look into them and be your own advocate

CMS specifies that only 28-day or 30-day supplies are covered per fill, and that switching between covered GLP-1 drugs triggers a new prior authorization